Straits Times Index
3,300.00 -4.00 (-0.12%) S&P 500
5,496.54 +9.51 (+0.17%) Dow
38,897.23 +62.37 (+0.16%) Nasdaq
17,892.38 +30.15 (+0.17%) Bitcoin USD
64,932.21 +30.28 (+0.05%) CMC Crypto 200
1,347.56 -35.10 (-2.54%)
ResMed Inc. (RMD.MX)
| Previous close | 3,900.00 |
| Open | 3,900.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 3,900.00 - 3,900.00 |
| 52-week range | 2,671.39 - 4,012.00 |
| Volume | |
| Avg. volume | 3 |
| Market cap | 574.692B |
| Beta (5Y monthly) | 0.69 |
| PE ratio (TTM) | 32.57 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 36.03 (0.92%) |
| Ex-dividend date | 08 May 2024 |
| 1y target est | N/A |
- GlobeNewswire
PAP Therapy Reduces Hospitalizations by 31% and ER Visits by 23% for People with Obstructive Sleep Apnea and Comorbid Insomnia
ResMed studies presented at SLEEP 2024 also revealed a 17% prevalence of insomnia among adults in North America, Latin America, and the Caribbean, and a higher rate of depression in women with OSASAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- In collaboration with leading medical researchers from around the world, ResMed (NYSE: RMD, ASX: RMD) presented 13 new clinical studies at SLEEP 2024, the annual joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society. Held in H
- GlobeNewswire
Developed in Collaboration with Leading Scientists, New ResMed-Supported Research at ATS 2024 Provides Evidence of the Effectiveness and Critical Role of Positive Airway Pressure Therapy
Among 26 ResMed-supported abstracts, these were the highlights: New findings show positive airway pressure (PAP) therapy reduced risks of death and hospitalization for patients with obstructive sleep apnea (OSA)Prevalence of OSA in the United States expected to increase 26.7% in men and women aged 30 –70Real-world trends of glucagon-like peptide-1 (GLP-1) receptor agonist and PAP therapy use show patients who were adherent to their GLP-1 medication had higher levels of PAP therapy use than those
- GlobeNewswire
ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- When: May 17–22, 2024Where: San Diego Convention Center (SDCC) | 111 Harbor Dr. San Diego, CA 92101 Marriott Marquis San Diego Marina | 333 West Harbor Dr. San Diego, CA 92101 Research: 26 ResMed-supported abstracts will be presented at ATS. Full list below. Highlights: Treatment of Sleep-Disordered Breathing with Adaptive Servo-Ventilation (READ-ASV) in Opioid Users – a European Registry Sunday May 19, 2024, 9:15 a.m. - 11:15 a.m., SDCC 32A-BPresented
